患者様やご家族など一般の方向け臨床・治癒情報サイト 臨床研究情報ポータルサイト

ENGLISH
×

情報をクリップできます

治験情報をこちらのホームページで一時的にクリップすることが出来ます。

海外の治験の状況「1」での検索結果

絞り込み

11240件の検索結果
  • 進捗状況
  • 試験名
  • 対象疾患名
  • 地域
  • 登録日
  •  
  • Not Recruiting

  • Durable response therapy evaluation for early or new onset type 1 diabetes mellitus
  • Otelixizumab is being developed for the treatment of patients with autoimmune T1DM with residual beta cell function (RBCF), with the goal of preserving RBCF in this patient population. There are currently no approved treatments for this indication. Approved treatments for T1DM in the EU are insulins or insulin analogues. MedDRA version: 14.0 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
  • Canada, Denmark, Finland, Germany, Italy, Spain, Sweden, United Kingdom, United States
  • 2008-07-07